Cardiac Amyloidosis Market Report 2026

Cardiac Amyloidosis Market Overview

• Cardiac Amyloidosis market size has reached to $5.73 billion in 2025 • Expected to grow to $8.71 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: Impact Of The Growing Geriatric Population On The Market • Market Trend: AI-Powered Software Revolutionizes Early Disease Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cardiac Amyloidosis Market?

Cardiac amyloidosis is a condition where abnormal amyloid protein deposits in the heart tissue, leading to stiffening and impaired function. This results in heart failure, arrhythmias, and other cardiovascular complications. Early diagnosis and treatment are crucial to managing symptoms and slowing disease progression. The main types of cardiac amyloidosis are light-chain amyloidosis and transthyretin amyloidosis. Light chain amyloidosis (AL amyloidosis) is a disorder where misfolded immunoglobulin light chains form amyloid deposits in organs, including the heart, leading to dysfunction and potential organ failure. Treatment options include chemotherapy, surgery, supportive care, stem cell transplant, and targeted therapy and the disease is primarily managed in hospitals, ambulatory surgical centers, and clinics.

What Is The Cardiac Amyloidosis Market Growth Forecast?

The cardiac amyloidosis market size is expected to see strong growth in the next few years. It will grow to $8.71 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing development of disease-modifying therapies, rising adoption of genetic testing, expansion of specialized amyloidosis treatment centers, growing investment in rare disease research, increasing focus on personalized cardiac therapies. Major trends in the forecast period include increasing focus on early and accurate diagnosis, rising adoption of advanced cardiac imaging techniques, growing use of biomarker-based screening, expansion of targeted therapeutic approaches, enhanced awareness among cardiologists.

Global Cardiac Amyloidosis Market Segmentation

1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis 2) By Treatment: Chemotherapy, Supportive Care, Stem Cell Transplant, Targeted Therapy 3) By End-User: Hospitals, Clinics Subsegments: 1) By Light Chain Amyloidosis: AL (Immunoglobulin Light Chain) Amyloidosis with Cardiac Involvement, AL Amyloidosis without Cardiac Involvement 2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)

What Is The Driver Of The Cardiac Amyloidosis Market?

The increasing geriatric population is expected to propel the growth of the cardiac amyloidosis market going forward. The geriatric population refers to older adults, typically aged 65 and above, who may require specialized healthcare and support due to aging-related changes. The geriatric population is increasing due to rising life expectancy, advancements in healthcare, and declining birth rates. The increasing geriatric population raises the prevalence of cardiac amyloidosis, as aging is a major risk factor for amyloid protein accumulation in the heart. For instance, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Therefore, the increasing geriatric population will propel the cardiac amyloidosis industry.

Key Players In The Global Cardiac Amyloidosis Market

Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Neurimmune AG, Attralus Inc., Oncopeptides, SOM Biotech, Amylyx Pharmaceuticals, AstraZeneca plc, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb Company, AbbVie Inc., Roche Holding AG, Johnson & Johnson, CSL Limited

Global Cardiac Amyloidosis Market Trends and Insights

Major companies operating in the cardiac amyloidosis market are focusing on technological innovations, such as artificial intelligence (AI)-based software-only diagnostic tools, to enhance early detection and improve clinical outcomes for patients with this underdiagnosed disease. An artificial intelligence (AI)-based, software-only medical device that detects cardiac amyloidosis is a diagnostic tool that uses artificial intelligence to analyze echocardiographic images and identify signs of the disease without requiring additional hardware or extensive clinical data. For instance, in November 2024, Ultromics Ltd., a UK-based health technology company, secured FDA clearance for EchoGo Amyloidosis, an AI-powered clinical tool for early cardiac amyloidosis detection. It is the first device in the FDA's Total Product Lifecycle Advisory Program (TAP) to receive marketing authorization. Using artificial intelligence, EchoGo Amyloidosis analyzes echocardiograms to detect the disease from a single clip, addressing the urgent need for earlier diagnosis before it progresses unnoticed.

What Are Latest Mergers And Acquisitions In The Cardiac Amyloidosis Market?

In January 2024, Ultromics Ltd., a UK-based health technology company, partnered with Pfizer Inc. to advance the development of its Echo AI algorithm for early cardiac amyloidosis detection. This collaboration aims to improve diagnostic accuracy and patient outcomes. Pfizer Inc. is a US-based pharmaceutical company that develops and manufactures medicines for diseases such as cardiac amyloidosis and consumer health care products.

Regional Outlook

North America was the largest region in the cardiac amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cardiac Amyloidosis Market?

The cardiac amyloidosis market consists of revenues earned by entities by providing services such as early diagnosis through imaging and biomarker testing, medication management, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac amyloidosis market also includes sales of diagnostic imaging tools, biomarker testing kits, and disease-modifying therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cardiac Amyloidosis Market Report 2026?

The cardiac amyloidosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac amyloidosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.